公开(公告)号：US20190169306A1

公开(公告)日：2019-06-06

申请号：US16321367

申请日：2017-07-28

Applicant: University of Southampton

Inventor： Martin John Glennie ,  Aymen Al-Shamkhani ,  Mark Steven Cragg ,  Sean Hua Lim

IPC: C07K16/28 ,  A61P35/00

Abstract: The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.